Fermentation, isolation and characterization of antibiotic PR-1350.
A number of strains of Oidiodendron truncatum was shown to produce a new antibiotic, PR-1350, which was isolated in the form of an amorphous powder either directly or via a crystalline monomethanolate, PR-1381, which in solution is reconverted to the parent compound. The antibiotic inhibits a broad spectrum of Gram-positive and Gram-negative bacteria in vitro, and has been shown to be active against P-388 lymphocytic leukemia in mice. Biosynthetic considerations based on the results of [1-13C]acetate incorporation indicate that the antibiotic is a diterpene of the clerodane type.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000302:isolation & purification* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D004224:Diterpenes / Q000096:biosynthesis / Q000302:isolation & purification / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005285:Fermentation; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D008826:Microbial Sensitivity Tests; D003904:Mitosporic Fungi / Q000254:growth & development*; D013045:Species Specificity
D000900:Anti-Bacterial Agents; D004224:Diterpenes; C039027:clerocidin